UCB Announces Start of Phase III Program with Epratuzumab for Patients with Moderate to Severe SLE
Thursday, January 13, 2011
Brussels, and Morris Plains, New Jersey - regulated information - UCB (EURONEXT: UCB) and U.S. based partner Immunomedics Inc. (NASDAQ: IMMU) today announced the enrollment of the first patient into EMBODY™ 1, one of two pivotal phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE). Patient enrollment for EMBODY™ 2 has also begun.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms